Save time and jump to the most important pieces.
SC 13G/A - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)
SC 13G/A - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)
SC 13G/A - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)
Brookline Capital Management reiterated coverage of Caladrius Biosciences with a rating of Buy and set a new price target of $10.00 from $7.00 previously
Brookline Capital reiterated coverage of Caladrius Biosciences with a rating of Buy and set a new price target of $10.00 from $7.00 previously
Company to commence trading on The Nasdaq Capital Market under Ticker Symbol "LSTA" Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens Board of Directors and Executive Leadership Team, appointing seasoned biopharmaceutical and clinical development industry executives BASKING RIDGE, N.J. and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius") and Cend Therapeutics, Inc. ("Cend") today announced that the proposed merger of the two companies has closed following the approval of Caladrius' stockholders on September 13, 2022. The merged company will operate as Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held September 13, 2022, its stockholders approved all of the merger-related proposals, including: (i) the Agreement and Plan of Merger and Reorganization, dated as of April 26, 2022, by and among Caladrius and Cend Therapeutics ("Cend"), and the transactions contemplated thereby, including the Merger and the issuance of shares of Caladrius' common stock to Cend's stockholders pursuant to the Agreement and Plan of Merge
BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will participate in the following investor events: H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022)Location: Lotte New York Palace Hotel in New York City (Hybrid conference)Presentation format: In-person and live/archived webcastPresentation Date/Time: Wednesday, September 14, 2022, at 12:00 p.m. ESTWebcast Link: https://bit.ly/3ARcXnjFor m
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the appointment of Todd Girolamo to its Board of Directors. Girolamo is a seasoned attorney and biopharmaceutical executive specializing in health-related products, currently serving as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary for Caladrius Biosciences, Inc. (NASDAQ:CLBS). "Mr. Girolamo will bring invaluable legal, finance and biopharmaceutical development insight and leadership to our Board," said
BASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced the appointment of Dr. Kristen K. Buck as the Company's Chief Medical Officer ("CMO"). Dr. Buck joins Caladrius from ICON plc ("ICON"), a global provider of drug and device development and commercialization services to the pharmaceutical, biotechnology and medical device industries. During her time at ICON, Dr. Buck served as its CMO, where she represented the company's position on key scientific, ethical, and medical govern
NEW YORK, Dec. 2, 2020 /PRNewswire/ -- HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today announced the appointment of Joseph Talamo as chief financial officer and the promotion of Ari Nowacek, M.D., Ph.D., to chief business officer. "We're pleased to welcome Joe to the HiberCell team and have Ari take on an expanded role as chief business officer," said Alan C. Rigby, Ph.D., co-founder and chief executive officer of HiberCell. "Joe has a track record of successful financial leadership and we're pleased to have him on board during a tremendous period of organizational growth. As a co-founder o
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
10-Q - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
S-8 - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "The second quarter of 2022 was a transformative and energizing quarter for Caladrius with the announcement of our
BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three and six months ended June 30, 2022, on Thursday, August 4, 2022, at 4:30 p.m. (EDT). The Company is utilizing a new conference call service. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details for dial-in options. To avoid d
Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next development steps for XOWNA® to be announced by year-end 2022 following regulatory and business review Caladrius Management will host a conference call tomorrow, May 24th at 8:15 a.m. EDT BASKING RIDGE, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company has suspended patient enrollment in its Phase 2b study of XOWNA®, known as
Gainers AMTD Digital Inc. (NYSE:HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news. Avenue Therapeutics, Inc. (NASDAQ:ATXI) surged 53.2% to close at $0.3562. AMTD IDEA Group (NYSE:AMTD) surged 50% to close at $1.95 on Wednesday. Aileron Therapeutics, Inc. (NASDAQ:ALRN) rose 42.2% to settle at $0.2702. Aileron Therapeutics, last month, posted a Q2 loss of $0.09 per share. Dawson Geophysical Company (NASDAQ:DWSN) gained 40.2% to close at $1.57. Akerna Corp. (NASDAQ:KERN) shares gained 26.9% to close at $0.1650 on Wednesday after gaining 8% on Tuesday. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM
Gainers Avenue Therapeutics (NASDAQ:ATXI) stock rose 77.1% to $0.41 during Wednesday's regular session. Avenue Therapeutics's stock is trading at a volume of 56.8 million shares as of 13:30 EST. This is 18245.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.0 million. bioAffinity Technologies (NASDAQ:BIAF) stock increased by 51.64% to $6.28. The current volume of 42.3 million shares is 800.8% of bioAffinity Technologies's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $17.1 million. NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 2
During Wednesday's session, 265 companies made new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Alphabet (NASDAQ:GOOG) was the largest company by market cap to set a new 52-week low. First Wave BioPharma (NASDAQ:FWBI) was the smallest firm on a market cap basis to set a new 52-week low. Vintage Wine Estates (NASDAQ:VWE) shares dropped the most, trading down 43.13% to reach its new 52-week low. Westrock Coffee (NASDAQ:WEST) saw the sharpest rebound, as shares ascended 0.0%, reversing after hiting a new 52-week low. Stocks that set new 52-week lows on Wednesday are as follows: Alphabet (NASDAQ:GOOG) stock hit $104.50 on Wednesday morning, setting a new 52-week low